Study suggests possible link between two Type 2 diabetes drugs and pancreatic cancer

link to article

Public release date: 16-Sep-2011
Contact: Enrique Rivero
University of California - Los Angeles Health Sciences
Study suggests possible link between two Type 2 diabetes drugs and pancreatic cancer

Two newer drugs used to treat Type 2 diabetes could be linked to a significantly increased risk of developing pancreatitis and pancreatic cancer, and one could also be linked to an increased risk of thyroid cancer, according to a new UCLA study.

Researchers from the Larry L. Hillblom Islet Research Center at UCLA examined the U.S. Food and Drug Administration's database for adverse events reported between 2004 and 2009 among patients using the drugs sitagliptin and exenatide. They found a six-fold increase in the odds ratio for reported cases of pancreatitis with these drugs, compared with four other diabetes therapies they used as controls. They also found that patients who took the two drugs were more likely to have developed pancreatic cancer than those who were treated with the other therapies.

The study is published in the journal Gastroenterology.

"We undertook these studies because several studies in animal models by several investigators had suggested that this form of therapy may have unintended actions to promote growth of the ducts (tubes) in the pancreatic gland that convey digestive juices from the pancreas to the gut," said Dr. Peter Butler, director of the Hillblom Center and a study co-author. "This is a concern if it happens in humans since it might be expected to increase the risk for pancreatitis and pancreatic cancer. While the FDA data base has limitations, it does have advantages in being very large, openly accessible and independent from companies that market the drugs.

"Taken together the animals studies and the FDA data base analysis suggest that further work needs to be undertaken to at least rule out that this now widely available new drug class for diabetes does not increase the risk of pancreatic cancer," Butler, who is also a member of UCLA's Jonsson Comprehensive Cancer Center, added.

[...]

..